Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

1.1K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

1.3K
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
1.3K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

676
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
676
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

2.4K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.4K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

525
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
525

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adhesive tape loops.

Soft matter·2026
Same author

Protocol for deriving proliferating primary fibroblast cultures from Malabar red snapper larvae for cytogenetic analysis.

STAR protocols·2026
Same author

The placental tryptophan pathway across gestation: implications for pregnancy outcomes.

Human reproduction update·2026
Same author

Hydroxychloroquine as an adjunct therapy in the management of type 2 diabetes in pregnancy: study protocol for a randomised controlled trial.

BMJ open·2026
Same author

Reducing Perinatal Mortality in Victoria, Australia: Early Insights From the Safer Baby Bundle Implementation.

The Australian & New Zealand journal of obstetrics & gynaecology·2025
Same author

An intelligent, compact wearable pressure-strain combo sensor system for continuous fetal movement monitoring.

Science advances·2025

Related Experiment Video

Updated: Mar 10, 2026

Ultrasound Assessment of Endothelial-Dependent Flow-Mediated Vasodilation of the Brachial Artery in Clinical Research
08:42

Ultrasound Assessment of Endothelial-Dependent Flow-Mediated Vasodilation of the Brachial Artery in Clinical Research

Published on: October 22, 2014

28.1K

The effects of hydroxychloroquine on endothelial dysfunction.

Rahana Rahman1, Padma Murthi2, Harmeet Singh3

  • 1The Ritchie Centre, Hudson Institute of Medical Research, 27-31 Wright Street, Clayton 3168, Melbourne, VIC, Australia; Department of Obstetrics and Gynaecology, School of Clinical Sciences, Monash University, Monash Medical Centre, 246 Clayton Road, Clayton 3168, Melbourne, VIC, Australia; Department of Obstetrics and Gynaecology, Faculty of Medicine, National University of Malaysia, Jalan Yaacob Latiff, Bandar Tun Razak, 56000 Cheras, Kuala Lumpur, Malaysia.

Pregnancy Hypertension
|December 13, 2016
PubMed
Summary

Hydroxychloroquine reduces inflammation and protects endothelial cells. This study suggests its potential as a therapy for preeclampsia, a condition involving endothelial dysfunction.

Keywords:
Endothelial dysfunctionEndothelin-1HydroxychloroquinePreeclampsiaPreeclamptic serumTNF-α

More Related Videos

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
07:46

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000

Published on: October 15, 2010

44.6K
Ultrasound Assessment of Endothelial Function: A Technical Guideline of the Flow-mediated Dilation Test
06:35

Ultrasound Assessment of Endothelial Function: A Technical Guideline of the Flow-mediated Dilation Test

Published on: April 27, 2016

18.9K

Related Experiment Videos

Last Updated: Mar 10, 2026

Ultrasound Assessment of Endothelial-Dependent Flow-Mediated Vasodilation of the Brachial Artery in Clinical Research
08:42

Ultrasound Assessment of Endothelial-Dependent Flow-Mediated Vasodilation of the Brachial Artery in Clinical Research

Published on: October 22, 2014

28.1K
Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
07:46

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000

Published on: October 15, 2010

44.6K
Ultrasound Assessment of Endothelial Function: A Technical Guideline of the Flow-mediated Dilation Test
06:35

Ultrasound Assessment of Endothelial Function: A Technical Guideline of the Flow-mediated Dilation Test

Published on: April 27, 2016

18.9K

Area of Science:

  • Pharmacology
  • Immunology
  • Vascular Biology

Background:

  • Hydroxychloroquine is an antimalarial drug with anti-inflammatory and immunomodulatory properties.
  • It is commonly prescribed for autoimmune diseases like systemic lupus erythematosus.
  • Previous research indicates hydroxychloroquine offers protective effects on endothelial cells.

Purpose of the Study:

  • To evaluate the endothelial protective capacity of hydroxychloroquine.
  • To investigate its effects in an in vitro model simulating preeclampsia-induced endothelial dysfunction.

Main Methods:

  • Utilized an in vitro model involving tumor necrosis factor-alpha (TNF-α) and serum from preeclamptic patients.
  • Assessed the impact of hydroxychloroquine on the production of TNF-α and endothelin-1 (ET-1).
  • Examined hydroxychloroquine's effect on TNF-α-induced impairment of angiogenesis.

Main Results:

  • Hydroxychloroquine significantly decreased the production of TNF-α.
  • It substantially lowered endothelin-1 (ET-1) levels induced by TNF-α and preeclamptic serum.
  • The drug effectively mitigated angiogenesis impairment caused by TNF-α.

Conclusions:

  • Hydroxychloroquine demonstrates significant endothelial protective effects in an in vitro model.
  • These findings support exploring hydroxychloroquine as a potential adjuvant therapy for preeclampsia.
  • Further clinical assessment is warranted to confirm its efficacy in managing preeclampsia.